Background-Obesity is associated with increased mortality following lung transplantation and is a relative contraindication to transplant. Whether weight reduction prior to transplantation ameliorates this risk is unknown. Our objective was to determine whether weight loss prior to lung transplantation improves survival.
Introduction
Median survival following lung transplantation remains suboptimal at approximately 5.5 years (1). Prior studies have demonstrated higher mortality among lung transplantation recipients who are obese (defined as a Body mass index -BMI ≥ 30 kg/m 2 ) (2). These results have been confirmed in larger trials (3, 4) . More recently, obese lung transplant recipients have been found to have a two-fold higher risk for developing primary graft dysfunction (5, 6) . Hence, obesity is considered a relative contraindication for lung transplantation (7) . Obesity continues to be a major public health problem in the United States with more than 32% of the adult population categorized as obese (8) . It is therefore expected that management of the obese candidate will be a common occurrence. It is unclear if weight loss prior to lung transplantation ameliorates the increased risk of mortality. Improving lung transplant outcomes by normalizing modifiable risk factors such as obesity deserves further study. Our objective was to determine if weight loss prior to lung transplant is associated with improved survival. Some of the results have been previously reported in abstract form (9) .
Materials and Methods

Patient Selection
We reviewed a retrospective cohort of research consenting patients who underwent single and double lung transplantation at Mayo Clinic, Rochester, MN or Jacksonville, FL, between 1/1/2000 and 11/5/2010. The study was approved by Institutional Review Board of Mayo Clinic (IRB 10-007684).
Inclusion criteria and Exclusion criteria
Patients who were 18 years or older at the time of lung transplantation were included in the study. Retransplantation or multi-organ transplant candidates were not included. Patients with an initial BMI <18.5 kg/m 2 were excluded from survival analysis.
Data Collection
Demographic data, transplant diagnosis and type including secondary pulmonary hypertension, transplant details, BMI at the date of initial evaluation and the date of transplantation, creatinine prior to transplantation, pre-existing diabetes mellitus or prednisone use, lung allocation score (LAS), and need for intensive care unit (ICU) or mechanical ventilation prior to transplant were abstracted. We also abstracted postoperative ICU and mechanical ventilator days, date of last follow up visit or communication, and date and cause of death. For a post-hoc analysis examining post-transplant weight gain we abstracted weights at six and twelve months.
Definitions
We defined normal weight as a BMI between 18.5 and 24.9 kg/m 2 . We defined overweight as a BMI between 25 and 29.9 kg/m 2 . We defined obese as a BMI ≥ 30 kg/m 2 . Diagnostic categories included: COPD, cystic fibrosis, idiopathic pulmonary fibrosis, pulmonary fibrosis (other), lymphangiomyomatosis, pulmonary arterial hypertension (PAH), sarcoidosis, bronchiolitis obliterans, eosinophilic granuloma, bronchiectasis, immotile cilia syndrome, bronchoalveolar cell carcinoma, and silicosis. Diagnoses were further separated into restrictive diseases (idiopathic pulmonary fibrosis, pulmonary fibrosis other, and sarcoidosis with fibrosis). In addition non-PAH patients with a resting pulmonary artery mean pressure on right heart catheterization greater than or equal to 25 mm Hg were defined as having secondary pulmonary hypertension.
Standard care of overweight and obese patients
All transplant patients meet with a registered dietician and are required to enroll in pulmonary rehabilitation as part of our standard pre-transplant protocol. Overweight and obese patients receive patient education regarding diet and exercise and are encouraged to lose weight prior to lung transplantation.
Data Analysis
A statistical software package (JMP, version 9; SAS 9.2 Institute Inc; Cary, NC; R 2.14) was used for data analysis. Median and Interquartile Range (IQR) for continuous variable and frequency and percentage for categorical variables were used to summarize the data. Wilcoxon Signed Rank was used for weight change comparisons. Time to death or last follow-up was analyzed using Cox Proportional Hazard model and Kaplan-Meier methods. P-values less than 0.05 were considered statistically significant. Linear regression was performed using log transformation models to evaluate ICU days and mechanical ventilator days. Model selection was done using stepwise model selection on clinically important predictors excluding variables that provided no significant improvement in the quality of the model. The Cox Model was adjusted for relevant clinical covariates (age, sex, and race).
Results
Demographics
Patient characteristics are summarized in Table 1 . Three hundred and fifty-five patients satisfied the inclusion and exclusion criteria. Of these, 351 patients had data for BMI at the time of transplant evaluation and 341 patients had data for BMI at the time of lung transplant. Final cohort size for weight change analyses were therefore 341 patients. Median age at transplantation was 59 years, interquartile range (IQR) 52 -65 years. Fifty-five percent were male and 88% were white. Thirty-seven percent (N=130) underwent transplantation for chronic obstructive pulmonary disease and 38% (N=134) underwent transplantation for idiopathic pulmonary fibrosis. Fifty-two percent (N=184) underwent single lung transplantation while the remainder underwent double lung transplantation. Median lung allocation score (LAS) was 39.8 (IQR 34.4 to 54.5). LAS was not available in 101 patients due to the date of transplant.
Pre-transplantation change in BMI
Thirty-eight percent had a BMI in the normal range, while 34% were overweight and 22% were obese at initial evaluation (see Table 2 ). BMI data was not available in four patients. At transplantation 43% had BMI ≤ 24.9 kg/m 2 , 42% were overweight and 9% remained obese. Sixty-four percent had a decrease in BMI before transplantation. Median decrease in BMI in the entire group was 0.6 kg/m 2 (IQR −0.2 to 2.15). However, in the obese patients the median decrease in BMI was 2.9 kg/m 2 (IQR 1.4 to 4.5), corresponding to weight loss of 8.5 kg (IQR 4.0 to 12.6 Kg). Fifty-six percent (N=41) of obese patients were able to lose weight and achieve a BMI ≤ 29.9 kg/m 2 . The median interval between the initial evaluation and lung transplantation was 272 days (IQR 115 to 534 days).
Differences between patients who lost weight and those who did not
We evaluated differences between patients able to achieve weight loss and those that did not (Table 3) . Patients did not differ with respect to use of bypass, ischemic time, or single versus bilateral lung transplant. Significant differences were found in patients by diagnosis (including presence of restrictive disease and secondary pulmonary hypertension) and in BMI at evaluation and at transplant.
Change in BMI and Survival
Simple Cox model and time-dependent models of survival were constructed to evaluate the effect of BMI reduction following lung transplantation. Median survival was 5 years representing 157 deaths in 329 patients. Figure 1 demonstrates this survival data categorized by BMI. The simple Cox model shows that after adjusting for demographics (age, sex, and race) and clinical information (initial BMI and days spent on mechanical ventilator) a one unit reduction in pre-transplant BMI was associated with reduced risk of death, shown in Table 4 [Hazard Ratio (HR): 0.89; 95% CI 0.82 -0.96; p-value = 0.004]. When looking more closely at the reduction in pre-transplant BMI effect on survival, we find weak evidence that the effect varies over time. Variables such as recipient diagnosis (including secondary pulmonary hypertension), pre-operative use of steroids, and ischemic time were not significant predictors of survival and were therefore not included in the model. Although single versus bilateral transplant and use of bypass were important in univariate analysis, they were not important variables in the multivariate model. Interestingly, when we split the analysis for patients with a baseline BMI ≤ 24.9 kg/m 2 and baseline BMI ≥ 25 kg/m 2 , weight loss in patients with a baseline BMI ≥ 25 kg/m 2 demonstrated a survival benefit (HR= 0.85; 95% CI 0.77 to 0.95; p = 0.003) whereas weight loss in patients with a baseline BMI ≤ 24.9 kg/m 2 did not (HR= 0.95; 95% CI 0.81 to 1.12; p=0.55) ( Table 4 ). The most common cause of death was respiratory failure regardless of BMI category (Table 5) .
Change in BMI and immediate post-operative outcomes
Weight loss pre-transplant was associated with improvement in perioperative morbidity. Median number of intensive care unit days and mechanical ventilator days post-transplant were 4 (IQR 3 to 8) and 2 days (IQR 1 to 3) respectively. After adjusting for age, a one-unit reduction in BMI was associated with a 4.4% decrease in the median number of days spent in the ICU (p= 0.06). In addition after adjusting for age and race, a one-unit reduction in BMI was associated with a 6.1% decrease in the median number of days spent on a mechanical ventilator (p= 0.02).
Post-transplant weight gain
At six months post-transplant patients did not gain weight with a mean difference of loss of −0.1 kg (p=0.84). Patients did gain weight at 12 months post-transplant with a mean increase of 3.3 kg (p<0.001). When analyzed by BMI weight gain was significantly different depending on BMI at transplant (p<0.001). Patients who were underweight at transplant (BMI <18.5 kg/m 2 ) gained a mean of 8.1 kg, while those with a BMI between 18.5 and 24.9 kg/m 2 gained a mean of 5.2 kg at 12 months post transplant. Overweight patients (BMI 25-29.9 kg/m 2 ) gained a mean of 1.6 kg while obese patients (BMI of 30 kg/m 2 or more at transplant) gained only a mean of 0.26 kg at 12 months following transplant. Interestingly patients who were obese or overweight at the time of evaluation (the same group that lost a median of 8.5 kg pre-transplant) gained only a median of 1.9 kg at 12 months.
Discussion
Our study demonstrated that weight loss prior to lung transplantation was associated with improved survival and decreased perioperative morbidity when adjusted for gender and age. Specifically, we found that a one-unit reduction in BMI pre-transplantation was associated with a reduced risk of death and decreased number of mechanical ventilator days. There was a trend towards decrease length of ICU stay. When evaluated further this mortality benefit was demonstrated in the patients with a baseline BMI ≥25 kg/m 2 (the patients who were obese or overweight at baseline). Interestingly this benefit appeared to persist over time with HR after four years demonstrating persistent significance.
In addition, our study addresses the feasibility of weight loss pre-transplant. In our cohort, sixty-four percent were able to achieve some weight loss with a median decrease in BMI of 2.9 kg/m 2 in obese patients. In fact, fifty-six percent of initially obese patients were able to lose weight to achieve a BMI < 29.9 kg/m 2 . This suggests that not only is weight loss associated with benefits for survival and morbidity, but it is a reasonable expectation for the majority of pre-transplant obese patients. Our median time between initial evaluation and transplant was 272 days suggesting that patients had a median of nine months to lose excess weight. Patients with a life expectancy of shorter duration may not be able to achieve equivalent weight loss.
Finally our study briefly looks at post-transplant weight gain. Our overweight and obese patients lost a median of 8.5 kg pre-transplant. At twelve months following these patients gained a median of 1.9 kg suggesting that most of the pre-transplant weight loss was sustained.
It has been reported previously that obese recipients have poor post-transplant survival (2-4). In addition, pre-transplant obesity is a risk factor for reduced physical quality of life after lung transplantation and for primary graft dysfunction. (6, 10) . Our study is the first to demonstrate evidence that pre-transplant obesity is a modifiable risk factor with respect to mortality. It is uncertain if weight loss pre-transplant improves post-transplant quality of life.
The mechanism by which obesity affects survival in lung transplantation recipients is not clear. The increased mortality risk appears to effect mortality in the early post-transplant period (11) . There is a general sense that the procedure is more protracted. Longer ischemic and cardiopulmonary bypass times would increase risk of primary graft dysfunction (PGD) and possibly effect mortality (3, 5, 12, 13) . Our study did not support this theory. There was no difference in patients with weight loss versus those without weight loss in terms of cardiopulmonary bypass use or ischemic time suggesting this was not the reason for the improved Hazard Ratio. Furthermore, ischemic time and use of cardiopulmonary bypass were not important predictors in the Cox Model.
Another theory to explain the increased mortality associated with obesity is that obese patients have increased risks of complications and respiratory failure perioperatively (14) . A decrease in ventilator days and trend towards decreased ICU length of stay in our study suggest that improvement in perioperative morbidity may be one mechanism of pretransplant weight loss benefit. Respiratory failure was the most common cause of death but this was true regardless of BMI.
Another theory of obesity's effect on survival is that obese patients may suffer from a proinflammatory state. It is known that obesity leads to increased production and release of proinflammatory mediators including leptin, resistin, vistafatin, interleukin 6 (IL-6), and Tumor necrosis factor-α (TNF-α) (15, 16) . In addition, fatty acids are increased contributing to Toll-like receptor activated systemic inflammation (16, 17) . In animal models leptin has been shown to produce acute lung injury and fibroproliferative changes leading to lung fibrosis (18, 19) . In obese recipients higher leptin levels are associated with development of PGD (6) . In fact, obese lung transplant recipients have a two-fold higher risk for developing PGD (5, 6) . PGD is associated with an increased risk of bronchiolitis obliterans syndrome (BOS), and the severity of PGD correlates with decreased survival (20, 21) . Acute lung injury sustained during PGD might predispose patients to BOS later and thus lead to worsened survival (20) . Due to the retrospective nature of our study we do not have leptin or adiponectin levels from our cohort to support or refute this hypothesis.
Obese patients may also suffer worsened survival due to a detriment in respiratory mechanics. Obesity decreases the total lung capacity, functional residual capacity and vital capacity, restricting lung volumes and leading to a decrease in respiratory system compliance with a tendency for atelectasis and worsening gas exchange (14) . The accumulation of visceral adiposity in patients with obesity increases the gastric pressure, decreases the tone of the lower esophageal sphincter, and increases the risk for aspiration, a known risk factor for BOS (22) (23) (24) (25) . We did find a difference in those with restrictive physiology versus those without when comparing patients who lost weight versus those who did not pre-transplant. Diagnosis, including restriction, was not ultimately important in the Cox Model.
Finally obesity may simply be associated with increased risk of co-morbidities. Compared with normal weight recipients, obese recipients are more likely to die from infection, cardiac disease, cancer and respiratory failure (3) . The presence of a longer-term mortality benefit in our study raises the question of whether this effect is due to changes in co-morbidities.
Weight loss prior to transplantation could reverse several of these risk factors and improve survival. Although we do include a cause of death break down by BMI further study is needed to explore this hypothesis.
Limitations
Our study is a retrospective cohort study and therefore we cannot control for all known or unknown confounding factors. For example, due to the retrospective nature we could not reliably adjust for transfusion rates in this study. It is possible that ability to achieve weight loss reflected a subset of patients that were in general more compliant with medical recommendations. Patients with increased medical compliance would potentially have other behaviors that could enhance outcomes. In addition it is possible that some of the patients suffered unintentional rather than volitional weight loss. Caution is warranted in such patients. Further study is needed to differentiate whether unintentional weight loss provides the same benefit to patients. Our routine practice is that obese and overweight patients meet with a registered dietician to receive standard education regarding weight loss. It is possible that patients who achieved weight loss were more physically active than those who did not achieve weight loss leading to a benefit from increased physical activity. At our transplant centers, however, all pre-transplant patients are encouraged to exercise and pulmonary rehabilitation enrollment is standard practice. Due to current selection criteria guidelines few patients in this study were morbidly obese (BMI ≥ 35 kg/m 2 ) and therefore further study is needed for that group of patients. Finally, the number of cystic fibrosis patients in our cohort was small (N=21) with only one obese cystic fibrosis patients at evaluation and therefore it is unknown whether our results are applicable to the cystic fibrosis population.
Conclusions
In summary, potential lung transplantation recipients who are obese and overweight should be encouraged to lose weight prior to lung transplantation. A reduction in the BMI prior to lung transplantation is associated with a reduction in the risk of death. Patients who are able to achieve a reduction in BMI have improved long-term survival. Weight reduction also demonstrates an improvement in post-transplant mechanical ventilator days and a trend towards reduced ICU stay. Future studies should focus on the cause of improved survival. Study of the impact of weight loss pre-transplant on inflammatory markers, primary graft dysfunction and subsequent development of BOS would be particularly beneficial. Furthermore studies evaluating for cause-specific mortality may further elucidate the impact of weight loss on obesity-related comorbidities. Finally, further study on the impact of weight loss pre-transplant on the post-transplant quality of life is also needed.
Acknowledgments funding sources
Financial support was provided by the Transplant Scholarly Physician Award, Mayo Clinic. This publication was made possible by CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH. Table 1 Baseline demographics are shown for various categories as indicated. 
